Javascript must be enabled to continue!
Plasma digoxin levels and ejection fraction in pediatric heart failure
View through CrossRef
Background Digoxin has long been prescribed in children with heartfailure, but its efficacy has not been evaluated. A previous study atthe Department of Child Health, Dr. Cipto Mangunkusumo Hospitalrevealed that plasma digoxin levels, following a maintenance doseof 15 μg/kg/d, were sub-therapeutic. Regarding its narrow margin ofsafety, the trend is to use digoxin in even lower dose. Thus, the drug’simpact on cardiac performance need to be evaluated.Objective To evaluate whether a lower maintenance dose of digoxin(10 μg/kg/d) is sufficient to achieve a therapeutic level and to assess forpossible correlations between plasma digoxin level and left ventricularejection fraction (LVEF) as well as fractional shortening (LVFS).Methods A cross-sectional study was conducted on 20 pediatricheart failure patients at the Department of Child Health, Dr. CiptoMangunkusumo Hospital, Jakarta, from January to May 2012. Plasmadigoxin levels were measured by ELISA method after one month ormore of treatment; LVEF and LVFS were measured by echocardiography.Correlations between plasma digoxin level and LVEF or LVFSwere analyzed by Spearman’s correlation test. The LVEF before andafter digoxin treatment were compared by paired T-test.Results Thirteen out of 20 patients had plasma digoxinlevels within therapeutic range (0.5-1.5 ng/mL; 95%CI0.599 to 0.898) and 7 had sub-therapeutic levels (<0.5 ng/mL; 95%CI 0.252 to 0.417). No significant correlationswere observed between plasma digoxin level and LVEF(r=-0.085; P=0.722) or LVFS (r=-0.105; P=0.659). There was asignificant increase in LVEF before [42.18 (SD 14.15)%] and afterdigoxin treatment [57.52 (SD 11.09)%], (P < 0.0001).Conclusion Most patients in this study have plasma digoxin levelswithin therapeutic range. There are no significant correlationsbetween plasma digoxin level at the time point of measurementand LVEF or LVFS. However, an increase of LVEF is observed inevery individual patients following digoxin treatment.
Paediatrica Indonesiana - Indonesian Pediatric Society
Title: Plasma digoxin levels and ejection fraction in pediatric heart failure
Description:
Background Digoxin has long been prescribed in children with heartfailure, but its efficacy has not been evaluated.
A previous study atthe Department of Child Health, Dr.
Cipto Mangunkusumo Hospitalrevealed that plasma digoxin levels, following a maintenance doseof 15 μg/kg/d, were sub-therapeutic.
Regarding its narrow margin ofsafety, the trend is to use digoxin in even lower dose.
Thus, the drug’simpact on cardiac performance need to be evaluated.
Objective To evaluate whether a lower maintenance dose of digoxin(10 μg/kg/d) is sufficient to achieve a therapeutic level and to assess forpossible correlations between plasma digoxin level and left ventricularejection fraction (LVEF) as well as fractional shortening (LVFS).
Methods A cross-sectional study was conducted on 20 pediatricheart failure patients at the Department of Child Health, Dr.
CiptoMangunkusumo Hospital, Jakarta, from January to May 2012.
Plasmadigoxin levels were measured by ELISA method after one month ormore of treatment; LVEF and LVFS were measured by echocardiography.
Correlations between plasma digoxin level and LVEF or LVFSwere analyzed by Spearman’s correlation test.
The LVEF before andafter digoxin treatment were compared by paired T-test.
Results Thirteen out of 20 patients had plasma digoxinlevels within therapeutic range (0.
5-1.
5 ng/mL; 95%CI0.
599 to 0.
898) and 7 had sub-therapeutic levels (<0.
5 ng/mL; 95%CI 0.
252 to 0.
417).
No significant correlationswere observed between plasma digoxin level and LVEF(r=-0.
085; P=0.
722) or LVFS (r=-0.
105; P=0.
659).
There was asignificant increase in LVEF before [42.
18 (SD 14.
15)%] and afterdigoxin treatment [57.
52 (SD 11.
09)%], (P < 0.
0001).
Conclusion Most patients in this study have plasma digoxin levelswithin therapeutic range.
There are no significant correlationsbetween plasma digoxin level at the time point of measurementand LVEF or LVFS.
However, an increase of LVEF is observed inevery individual patients following digoxin treatment.
Related Results
Clinical signs and symptoms of toxic serum digoxin levels in neonates
Clinical signs and symptoms of toxic serum digoxin levels in neonates
Digoxin is widely used in the treatment of congestive heart failure and some arrhythmias. Digoxin toxicity may occur easily because digoxin has a narrow therapeutic index. This ret...
Effect of Digoxin on Ejection Fraction in Elderly Patients with Congestive Heart Failure
Effect of Digoxin on Ejection Fraction in Elderly Patients with Congestive Heart Failure
To assess the effect of oral digoxin on left ventricular systolic function in elderly patients, radionuclide angiography was performed on 20 patients 74 years old or older before a...
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
ASSA13-13-6 Clinical Study of Prenatal Trans-Placental Digoxin Therapy For Fetal Heart Failure
ASSA13-13-6 Clinical Study of Prenatal Trans-Placental Digoxin Therapy For Fetal Heart Failure
Objective
Study the clinical efficacy and safety of transplacental digoxin therapy for foetal heart failure. Investigate the evaluation and treatment guiding valu...
Efficacy of SGLT2 Inhibitors in Heart Failure to Improve Ejection Fraction
Efficacy of SGLT2 Inhibitors in Heart Failure to Improve Ejection Fraction
Background: Heart failure with reduced ejection fraction is a major cause of morbidity, hospital admission, and cardiovascular mortality worldwide. Many patients end up with poor f...
Comorbidities and sex differences in chronic heart failure of ischemic etiology
Comorbidities and sex differences in chronic heart failure of ischemic etiology
Abstract
Background: Comorbidities and sex differences play a major role in chronic heart failure (CHF). However, it is unknown whether the prevalence of comorbidities diff...
Association of Digoxin Use at Norwood Discharge with Fontan Completion: A Study from the Pediatric Heart Network Public Dataset
Association of Digoxin Use at Norwood Discharge with Fontan Completion: A Study from the Pediatric Heart Network Public Dataset
Abstract
Background
Digoxin use after the Norwood procedure has been associated with improved interstage survival in hypoplasti...
Ten Years of Experience in Treating Patients With Digoxin Toxicity Without Using Digoxin Fab Antibody
Ten Years of Experience in Treating Patients With Digoxin Toxicity Without Using Digoxin Fab Antibody
Background: Digoxin is extensively prescribed for cardiac diseases, so its chronic or acute toxicity commonly occur. Although digoxin specific antibodies (anti-digoxin Fab) are rec...

